Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Inhibikase Therapeutics Inc (IKT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Inhibikase's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.5200 -0.0600    -3.80%
01/08 - Closed. Currency in USD
After Hours
1.5200
0.0000
0.0000%
21:10:04 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 83,516
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 1.4600 - 1.5600
Inhibikase 1.5200 -0.0600 -3.80%

Inhibikase Therapeutics Inc Company Profile

 
Get an in-depth profile of Inhibikase Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

16

Equity Type

ORD

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Contact Information

Address 3350 Riverwood Parkway SE Suite 1900
Atlanta, 30339
United States
Phone (678) 392-3419
Fax -

Top Executives

Name Age Since Title
Amit D. Munshi 57 2024 Independent Chairman
Dennis N. Berman 74 2020 Independent Director
Robert A. Hauser - - Member of Scientific Advisory Board
Valina L. Dawson - - Member of Scientific Advisory Board
Roy Lester Freeman 72 2020 Independent Director
Ted M. Dawson - - Member of Scientific Advisory Board
Pankaj Jay Pasricha - - Member of Scientific Advisory Board
Roberto Francesco Bellini 45 2024 Independent Director
David Canner 37 2024 Independent Director
Jeffrey H. Kordower - - Member of Scientific Advisory Board
Kenneth L. Marek - - Member of Scientific Advisory Board
Mark T. Iwicki 59 2025 CEO & Director
Arvind Kush 41 2024 Independent Director
Vincent E. Aurentz 57 2025 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IKT Comments

Write your thoughts about Inhibikase Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email